I and interleukin I (IL-I ) are 2 major pro inflamm atory cytok ines that have pathologic roles in rheumatoid arthritis (RA ). The man agem ent of RA has evol ved from the use of nonspec ific disease-modifying antirheumatic drugs (DMARDs) such as methotrexate to targeting specific cytokines with biologics such as TNF inhibitors (eg , etanercept. intliximab, adalimumab) and IL-I receptor antagonists (eg , anakinra). A variety of adverse effects has been reported with each of these drugs , ranging from minor local injection site reactions to severe life-threatening anaphylaxis. ' We describe a case of anaphylaxisfollowing 2 months of uninterrupted anakinra therapy in a patient with RA who demonstrated allergic manifestations to all commercially available anti-TNF therapies , sulfasalazine, and hydroxychloroquine. Although cases of anakinra-related hypersensitivity have been reported in patients in whom therapy was interrupted and then reintroduced.Pto our knowledge, this is the first reportof anaphylaxis withcontinuous therapy.
Case Report
A 46-year-old Indian woman with a 16-yearhistory of RA had poorly controlled disease despite treatment with DMARDs including methotrexate, hydroxychloroquine, and sulfasalazine. She had a history of recurrent eczematousdermatitis and lichensimplex chronicus. She denieda personal or family historyof asthma,hay fever,or antecubital and popliteal dermatitis. Hurrian leukocyte antigen (HLA)typing was significant for HLA-A*24 and B*1502. Outpatientmedications included methotrexate 25 mg/wk, folic acid 1 mg/day,prednisone 5 mg/day, clopidogrel 75 mg/day, aspirin 325 mg/day, alendronate 70 mg/wk,calcium carbonate 1250mg twice daily, multiplevitamin daily, extended-release nifedipine 30 mg/day, naproxen 500 mg twicedaily, and ferrous sulfate325 mg/day. She deniedthe recent use of over-the-counter medications or dietary supplements. Her height and weight were 157 em and 60 kg, respectively, and her serum creatinine level was stable at 0.9mgldL.
Because of continued active disease,as well as a history of allergic reactions to hydroxychloroquine and sulfasalazine, additional therapy with a number of biologic agentswas tried concurrently with methotrexate and prednisone. Beginning with intravenous infliximab 3 mg/kg monthly, she began to develop a progressivelyworsening pruritic, urticarial rash that wouldoccur within 30 minutes of the infusion and last for approximately 1 day.Although intravenous diphenhydramine 50 mg initially controlled these symptoms, infliximab was discontinued after only 3 doses when she experiencedan episode of orthostatichypotension, tachycardia, chills,and low-grade fever. Therapy was switchedto etanercept,which the patienttolerated for approximately 1 year. However, this medication was ineffective and was subsequently discontinued becauseof development of antinuclear antibodies (ANA) and high levels of double-stranded DNA (dsDNA) titer antibodies (>200 IU/mL), worsening Raynaud's phenomenon, and digital microinfarcts ( Figure I ). With cessation of etanercept, and initiation of warfarin, vasodilator therapy withnifedipine, and a tapering regimen of prednisone, these symptoms resolved.
After withdrawal of etanercept for approximately 5 weeks (>6 half-lives), the patient was started on daily anakinra 100 mg injections. Although she experienced moderate injection site reactions from the first dose, which gradually progressed into episodic pruritus and hives, she was able to tolerate the drug for 2 months and showed improvement in clinical symptoms. A component of the needle cover of prefilled anakinra syringes contains a latex derivative, but the patienthad no knownhistory of latexal-lergy. After 2 months, her allergic symptoms worsened so that, within 20 minutes of an anakinra injection, she abruptly developed perioral and facial swelIing with flushing, shortness of breath, dizziness, and generalized urticaria without any other identifiable etiologies. Although her neutrophil countwithin2 weeksprior to thisevent was normal, the eosinophil count was elevated, suggesting a possible allergicversus infectiousetiology. Likewise,her symptoms responded to intravenous hydration and treatment withepinephrine, diphenhydramine, and methylprednisolone. There were no abnormal laboratory findings, including negative ANA and dsDNAtiters.
Allergy testing with the skin prick method was performed, using anakinra,infliximab, etanercept, and adalimumab (anticipating potentialfuture use) with histamine and glycerinas the positiveand negative controls, respectively. The concentration of eachdrugusedforthe skinprick testwasidentical to theconcentration usedfordrugadministration, as this mostclosely reflected the actual dosing of the drug thatelicited the systemic reaction, without the needfor subcutaneous administration. Therefore,serialdilutions of the administered concentration werenot performed. The patient reacted to anakinra with a 9-mm diameterwheal and flare, compared with 7 mm for histamine, and had no responseto infliximab, etanercept, adalimumab, and control. Theseresults are consistent with a type I hypersensitivity immunoglobulin (Ig) E-mediated reaction ( Figure 2 ).
The patient was startedon adalimumab 40 mg subcutaneously every other week, following a negativeskin test. While thefirst dosedid notelicit any adverse symptoms, the second, third,and fourth injections resulted in localized site reactions, progressing from pruritus to a wheal with subsequent development of generalized hives. She denied chest pain, fever,or shortnessof breath. The reaction gradually subsided after discontinuation of adalimumab, treatment withdiphenhydramine, and increased prednisone dosing.
Discussion
Our patient experienced an anaphylactic reaction to anakinra and demonstrated unique allergic reactions to all 3 commercially available anti-TNF agents, as well as sulfasalazine and hydroxychloroquine. As observed in our patient, the most common adverse effectsassociated with infliximab are infusion-related reactions,typicallyoccurring within 1-2 hours of administration.' However, a delayed reaction may occur from I to 14 days following an infusion of infliximab.!Infusion reactions have been reported in up to 20% of patients, compared with a 10% incidence with placebo." Symptoms may includefever,chills, chest pain, hypotension, hypertension, dyspnea, pruritus, urticaria, and/or cardiopulmonary reactions, with less than I% of patients experiencing anaphylaxis,seizures, or erythematous rash. ' Although rapid onset of symptoms after starting infliximab infusions suggests an IgE-mediated type I hypersensitivityreactionF one study reported that infusion reactions are not Igfi-mediated,' To minimize infusion-related adverse events, infliximab should be administeredover more than 2 hours. If infusion reactionsoccur, symptoms may improve after slowingor discontinuing the infusion. Subsequentreinstitution of therapy at a lower infusion rate and/or premedication with antihistamines, acetaminophen, and/or corticosteroids may be considered. Since these interventions were unsuccessful in our patient, infliximab was discontinued and an alternative anti-TNF therapywas considered.
When we substituted etanercept for infliximab in our patient,her ANA and anti-dsDNA titers increasedand she developed worsening Raynaud's phenomenon and digital microinfarcts. The appearanceof new-onset ANA and ds-DNA antibodies occur in approximately II % and 15%of etanercept-treated patients compared with 5% and 4% of individuals receiving placebo,respectivelys-" As observed with our patient,titers usually normalize following discontinuation of etanercept. Although seroconversion is rarely associated with drug-induced lupus, patients sometimes develop lupus-like symptomsthat typically resolvefollowing drug withdrawal.":" It is postulated that TNF blockade may promotethe development of autoantibodiesIS and may impair TNF-mediated leukocyte expression of CD44 involved in apoptotic neutrophil clearance." Further, anti-TNF therapy may induce apoptosis of cells that express TNF, resulting in the releaseof nuclear-derived antigens."
Several case reports of cutaneous vasculitis associated with etanercept, similar to that seen in our patient, have been published.'4,'8. 23 One potential mechanism for anti-TNF therapy-induced vasculitis is the deposition of immune complexes of either antibodies to etanercept or autoantibodies in small capillaries, activating complement, and subsequently triggering a type 3 hypersensitivity reaction.'8,'9 This mechanism does not explain the development of ANA or antibodies to dsDNA. However, it has been suggested that TNF blockade may lead to a switch from the predominantThl profile ofT lymphocyte response in RA to a Th2response,common to other Th2lymphocytemediated vasculitic diseases, such as lupus and Wegener's granulomatosis." This same pathway associated with a change in the Th profilehas been proposedfor severalcase reports ofTNF blockade-associated atopic dermatitis. 24 ,25 Conversely,T cell lymphocyticvasculitis with a Th l-predominant profile has been reported in a patient with Crohn's disease," This particularcase was associated with increased systemic chemokines,defensins, cytokines, and angiogenesis factors; local activation of innate and adaptive immune responses; and highly active peripheral B cells.The authors postulated that aggressive TNF suppression may have promotedloss of immune tolerance to self.
Although anecdotal reports suggest that substitution with an alternative TNF blocker may not be associated with recurrenceof vasculitis ,26 cases of vasculitis resulting from the administration of both etanercept and infliximab have been described,therebysuggestingthe potential for a class effect I9 ,21. 2J and cross-sensitivity.Corticosteroids remain the standard treatment for systemic vasculitis in patients with RN7 and have been useful in cases of etanercept-induced vasculitis.":" Our patientrespondedto cessation of etanercept and a temporary increase in the dose of corticosteroids.
Since our patient continued to have active disease, we opted to initiate therapy with anakinra. Surprisingly,after tolerating therapyfor 2 months,she suddenlydevelopedan anaphylactic reaction, which was confirmed by the skin prick test. The patient subsequently responded to hydration, epinephrine, antihistamines, and corticosteroids, which is consideredstandardof care," Use of the Naranjo
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The Annals ofPharmacotherapy • 2009May, volume 43 • 969 probability scale found anakinrato be the probable cause of the patient's anaphylaxis." Since anakinrais produced by recombinant DNA technology using an Escherichia coli bacterial expression system," it is possible thatour patient may have had a hypersensitivity reaction to E. coli-derived proteins.However, she had no prior history of allergy to proteins synthesized by E coli. Rare reports of hypersensitivity to anakinra have occurred. 2 ,J , 30 One case involved a systemic reaction consisting of abdominal pain, dyspnea, and facial and abdominal erythema with pruritus 3 hours after reintroduction of anakinrain a patientwith a prior cutaneous reaction.' In a second case report in which anakinra therapy was interrupted,a severe immediate allergic reaction with urticarial lesions, edemaof the patient's feet and hands, and a pruritic tongueoccurred in a 7-year-oldgirl withjuvenile idiopathicarthritis once therapy was restarted.' She responded to drug withdrawal and corticosteroids. Anakinra therapy was reintroduced using a desensitization protocol.
Because abataceptand rituximab were either not availableor not usedin RA whenour case occurred, adalimumab was our next therapeutic consideration. Because it is a fully human monoclonal antibody with only rare reports «1 %) of anaphylactoid or fixed drug reactions,31,32 there wasthepotential thatour patient might tolerate adalimumab. However, beginning withthe second dose,she experienced symptoms of hypersensitivity ranging frominjection sitereactions to generalized hives. Urticarial reactions similarto those seenin our patient have been reported withadalimumab. 33.35 Therapy was again discontinued, necessitating the management of RA withmethotrexate monotherapy.
In addition to these multiple biologic agents,our patient reacted to hydroxychloroquine and sulfasalazine. Because of her intolerance to multiple medications and an allergy to a sulfonamide, it was initially questioned whether she might have a condition known as "multiple drug allergy syndrome," characterized by a propensity to react to different, chemically unrelated therapeutic agents," This clinical scenario is observed predominantly in females and in individuals with a history of intolerance to at leastone medication. Although acute urticaria and/or angioedema are the usual presenting symptoms, Stevens-Johnson syndrome, anaphylaxis, serum sickness, and immune-mediatedcytopenias may also occur.The syndromeappears to have a genetic predisposition that may includean increasedtendency to haptenize newly introduced antibiotics and small molecules to self-proteins, leading to increased risk for sensitization." Furthermore, although our patient was allergic to sulfonamides, the absence of hypersensitivity to other antibiotics makes her presentation unique. Interestingly, 8 patients intolerant to multiple drugs were also shownto havestrongwheal and flare reactions upon injection of autologous sera," Additionally, drug recognition in IgE-mediated reactions of some patients with multiple drug allergies may be related to the presence of tertiary and quaternary amino groups presenton many pharmacologicallyactiveagents,"
Future management for our patient includesavoidance of the biologics previously administered and possibly other drugs associated with E. coli-derived proteins, such as anakinra, as well as careful therapeutic decisions with close monitoring. The 3 anti-TNF agents that our patient received all share an IgG, structure. However, she also reacted to anakinra, a recombinant IL-I receptorantagonist with no structural similarities to the IgG molecule. It is plausiblethat, because anakinra is a recombinant protein expressed in bacteria, some contaminant may serve as a neo-antigen. In addition, unlikeendogenous IL-I RA or a recombinant protein expressed in eukaryotic cells,it is not glycosylated. Thus, portionsof its surface structure,with an additional methionine on the N-terminus, are exposed, otherwise hidden in the natural protein.
Currently, clinical or genetic predictors of toxicity to biologics are not known. Specific humanmajorhistocompatibility gene complex (HLA) phenotypes, such as HLA-A*24 and HLA-B*1502 in our patient,may be associated with susceptibility to certain drug allergies,such as dipyrone-induced agranulocytosis and carbamazepine hypersensitivity, respectively," The use of skin testingas a predictive measure for future reactions must be validated for each drug individually. Giventhe low rateof type I hypersensitivity reactions to anakinra, such validation cannotbe performed unless and until type I reactions to biologics become far more common.Moreover, positive and negative testsin patients who haveor have not had a reaction to anakinra simply cannot be interpreted and used as guidelines for therapy. However, pharmacogenetics has the potential to identify genetic variations associatedwith both improved therapeutic outcomes and safety. Although the influenceof several candidate genes on response to TNF inhibition have been studied,41.44 genetic data assessing polymorphisms associatedwith either toxicity or discontinuationof any biologic agent used in RA are limited. A recent report on IgE-mediated hypersensitivityto cetuximab identified galactose-n-I ,3-galactose as the antigen recognized by serumIgE antibodies that were present prior to the reactions," This oligosaccharide is found in biologics produced by mousecell linesand othersources.
Our case is a unique exampleof a patient with RA and multiple drug allergies who manifested distinct adverse reactions to several DMARDs and biologics, including an anaphylactic reaction to anakinra. This presented a difficult clinical management scenario that required introduction of each agent on a trial-and-error basis over a 4-year period. Hopefully, in the future, pharmacogenetics may help to better identify individuals at risk for multiple drug reactions and preclude unnecessary exposure to potentially harmful therapeutic options in similar patients. 
